PF Equity Holdings 2 B.V. 3
3 · Allogene Therapeutics, Inc. · Filed Sep 20, 2021
Insider Transaction Report
Form 3
PF Equity Holdings 2 B.V.
10% Owner
Holdings
- 22,032,040
Common Stock
[F1]
Footnotes (1)
- [F1]Shares acquired from its parent entity, Pfizer Inc. for no cash consideration.
Signature
Susan E. Grant, Attorney-in-fact on behalf of PF Equity Holdings 2 B.V.|2021-09-20